Analytical Data
-
基因名
F12
- Application
-
别名
F12；CFBP；FAM125A；Multivesicular body subunit 12A
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P00748
-
表达区间
20-372aa
-
氨基酸序列
IPPWEAPKEHKYKAEEHTVVLTVTGEPCHFPFQYHRQLYHKCTHKGRPGPQPWCATTPNFDQDQRWGYCLEPKKVKDHCSKHSPCQKGGTCVNMPSGPHCLCPQHLTGNHCQKEKCFEPQLLRFFHKNEIWYRTEQAAVARCQCKGPDAHCQRLASQACRTNPCLHGGRCLEVEGHRLCHCPVGYTGAFCDVDTKASCYDGRGLSYRGLARTTLSGAPCQPWASEATYRNVTAEQARNWGLGGHAFCRNPDNDIRPWCFVLNRDRLSWEYCDLAQCQTPTQAAPPTPVSPRLHVPLMPAQPAPPKPQPTTRTPPQSQTPGALPAKREQPPSLTRNGPLSCGQRLRKSLSSMTR
-
分子量
43.3 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
F12 (Factor XII) is a crucial protein involved in the intrinsic pathway of coagulation, playing a vital role in the initiation of blood clotting. Research into F12 has gained significant attention due to its implications in various pathological conditions, including thrombosis, sepsis, and inflammation. Unlike other coagulation factors, F12 is unique in that it can activate without the need for prior tissue injury, leading to the potential for inappropriate activation and thrombosis in certain individuals. The understanding of F12's structure and function has evolved, with studies exploring its role in the cascade of coagulation and the fibrinolytic system. Recent advancements in recombinant technology have enabled the development of F12-related therapeutic proteins, aiming to modulate its activity in clinical settings. The research on F12 is critical, not only for understanding coagulation disorders but also for developing innovative therapeutic strategies to prevent and treat thrombotic diseases, making it a promising target in hematology and cardiovascular medicine.
